Suppr超能文献

评估体外筛选工具在预测口服肽递送生物性能中的效用。

Assessing the Utility of In Vitro Screening Tools for Predicting Bio-Performance of Oral Peptide Delivery.

机构信息

Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., 126 East Lincoln Ave, Rahway, New Jersey, 07065, USA.

Department of NMR Structure Elucidation, Merck & Co., Inc., Kenilworth, New Jersey, USA.

出版信息

Pharm Res. 2019 Aug 26;36(10):151. doi: 10.1007/s11095-019-2682-8.

Abstract

PURPOSE

In this study we evaluated the utility of in-vitro screening tools for predicting the in-vivo behavior of six cyclic peptides with different solubility and permeability properties (BCS class II and III), intended for oral delivery in presence of permeation enhancer Labrasol.

METHODS

An in vitro flux assay was used to assess peptide permeation across a biomimetic, lipid-based membrane and in vivo studies in rats were used to determine oral peptide bioavailability in the presence of Labrasol.

RESULTS

The in vitro flux was significantly increased for BCS class III peptides, while it significantly decreased or remained unchanged for BCS class II peptides with increasing Labrasol concentrations. The different flux responses were attributed to the combination of reduced effective free peptide concentration and increased membrane permeability in the presence of Labrasol. In vivo studies in male Wistar-Hans rats indicated improved oral bioavailability at different extents for all peptides in presence of Labrasol. On comparing the in vitro and in vivo data, a potential direct correlation for BCS class III peptides was seen but not for BCS class II peptides, due to lower free concentrations of peptides in this class.

CONCLUSION

This study assessed the utility of in vitro screening tools for selecting peptides and permeation excipients early in drug product development. Graphical Abstract Graphical Abstract and Figure 1 contains small text.Graphical Abstract text is made larger. The Figure 1 text cannot be made larger.

摘要

目的

本研究评估了体外筛选工具在预测六种具有不同溶解度和渗透性特性(BCS 分类 II 和 III)的环状肽体内行为中的应用,这些肽旨在在渗透增强剂 Labrasol 的存在下口服给药。

方法

使用体外通量测定法评估肽穿过仿生脂质膜的渗透性,并使用大鼠体内研究在 Labrasol 存在下确定口服肽的生物利用度。

结果

随着 Labrasol 浓度的增加,BCS 分类 III 肽的体外通量显著增加,而 BCS 分类 II 肽的通量则显著降低或保持不变。不同的通量响应归因于有效游离肽浓度降低和 Labrasol 存在时膜通透性增加的组合。在雄性 Wistar-Hans 大鼠中的体内研究表明,所有肽在 Labrasol 存在下的口服生物利用度在不同程度上得到改善。在比较体外和体内数据时,对于 BCS 分类 III 肽可以看到潜在的直接相关性,但对于 BCS 分类 II 肽则没有,因为该类肽的游离浓度较低。

结论

本研究评估了体外筛选工具在药物产品开发早期选择肽和渗透增强剂的应用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验